H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

On May 28, H.C. Wainwright analyst Yi Chen initiated coverage of NeuroPace, Inc. (NASDAQ:NPCE) with a Buy rating and a price target of $18. The rating comes after the company released preliminary results for one-year data in NAUTILUS study.

On May 27, the company announced key results from its NAUTILUS study, the first clinical trial evaluating its RNS system for drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint at 12 weeks post-implant, demonstrating a low rate of serious adverse events and reinforcing the device’s established safety profile. The analyst noted that the system demonstrated significant seizure reduction in the clinical stage.

A close-up of a medical device being calibrated and tested in a clinical laboratory setting.

Moreover, NeuroPace, Inc. delivered robust results for the fiscal first quarter of 2025. The revenue grew more than 24% year-over-year to $22.52 million and surpassed expectations by $676,490, whereas the EPS of $-0.21 also exceeded consensus by $0.03. The analyst said that the stock has appreciated over 150% during the past year and the recent data from the study presents an attractive entry point for investors.

NeuroPace Inc. is a commercial-stage medical device company that develops the RNS system. RNS system is an implantable brain-responsive device designed to reduce or prevent seizures in people with drug-resistant epilepsy.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.